Biological Warfare

Doxycycline Gets Anthrax Labeling

Published in TB and Outbreaks Week, December 11th, 2001

The U.S. Food and Drug Administration is in the process of approving new labeling for doxycycline and other antibiotics to treat anthrax, in response to increasing national interest in antibiotic treatment options for anthrax, said Bioglan Pharma, Inc. The company's Adoxa (doxycycline) tablets are already available for this use.

Adoxa (doxycycline), traditionally marketed by Bioglan as an adjunctive treatment of severe acne, is a broad-spectrum antibiotic member of the tetracycline class, and is approved by the FDA for the treatment of anthrax (Bacillus anthracis) in all its forms, including cutaneous and inhalation anthrax (postexposure) in adults and children...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry